SAN JOSE, Calif., June 29, 2026
Anixa Biosciences, Inc. announced that the Korean Ministry of Intellectual Property (MOIP) has granted the company’s first South Korean composition-of-matter patent covering its investigational breast cancer vaccine, extending exclusive intellectual property protection through 2040. The patent, exclusively licensed from Cleveland Clinic, protects Anixa’s novel vaccine technology designed for the prevention and treatment of breast cancer and significantly expands the company’s global intellectual property portfolio. The newly issued patent strengthens Anixa’s commercialization strategy in Asia while reinforcing protection across one of the world’s fastest-growing breast cancer markets, where disease incidence continues to rise, particularly among younger women. The company believes the expanded patent estate will support future regulatory activities, strategic collaborations, licensing opportunities, and long-term global commercialization efforts.
Patent Strengthens Global Intellectual Property Portfolio
The newly granted Korean patent complements Anixa Biosciences’ existing intellectual property protections in the United States and other international markets, further strengthening its worldwide leadership in cancer vaccine innovation. According to Dr. Amit Kumar, Chairman and Chief Executive Officer of Anixa Biosciences, every new patent expands the company’s global foundation for developing its breast cancer vaccine while enhancing opportunities to collaborate with major pharmaceutical companies for worldwide commercialization. The company recently completed a Phase 1 clinical trial conducted at Cleveland Clinic, where the vaccine achieved its primary safety objectives, demonstrated favorable tolerability, and generated measurable immune responses in 74% of participants, supporting continued clinical development of the investigational therapy.
Novel Vaccine Targets Retired Protein Linked to Breast Cancer
Anixa’s breast cancer vaccine utilizes an innovative immunotherapy approach targeting human α-lactalbumin, a protein normally associated with lactation that becomes abnormally expressed in certain forms of breast cancer, particularly triple-negative breast cancer (TNBC). Developed by researchers at Cleveland Clinic and exclusively licensed to Anixa, the technology employs a unique “retired protein” strategy that aims to train the immune system to recognize and eliminate cancer cells while minimizing effects on healthy tissues. Unlike conventional cancer treatments that target established tumors, the investigational vaccine is designed to prevent tumor formation before cancer develops, potentially establishing a new preventive strategy for one of the world’s most common malignancies. Currently, no preventive breast cancer vaccine has been approved anywhere globally, highlighting the significance of this innovative research.
Advertisement
Global Expansion Supports Future Commercialization Strategy
Breast cancer remains the most commonly diagnosed cancer among women worldwide, and South Korea represents an increasingly important market due to rising incidence rates and a higher proportion of younger patients compared with many Western countries. By securing long-term patent protection through 2040, Anixa Biosciences is strengthening its ability to pursue international partnerships, regional licensing agreements, and future commercialization opportunities as clinical development advances. Beyond breast cancer, the company’s broader oncology vaccine platform includes investigational programs targeting ovarian, lung, colon, and prostate cancers, all based on its proprietary retired-protein immunotherapy approach. With expanding global intellectual property protection and encouraging early clinical findings, Anixa continues to position its vaccine platform as a potentially transformative advancement in cancer prevention and immunotherapy.
Source: Anixa Biosciences, press release
